Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction.
In factor IX residues 199-204 encompass one of six surface loops bordering its substrate-binding groove. To investigate the contribution of this loop to human factor IX function, a series of chimeric factor IX variants was constructed, in which residues 199-204 were replaced by the corresponding sequence of factor VII, factor X, or prothrombin. The immunopurified and activated chimeras were indistinguishable from normal factor IXa in hydrolyzing a small synthetic substrate, indicating that this region is not involved in the interaction with substrate residues on the N-terminal side of the scissile bond. In contrast, replacement of loop 199-204 resulted in a 5-25-fold reduction in reactivity toward the macromolecular substrate factor X. This reduction was due to a combination of increased K(m) and reduced k(cat). In the presence of factor VIIIa the impaired reactivity toward factor X was largely restored for all factor IXa variants, resulting in a more pronounced stimulation by factor VIIIa compared with normal factor IXa (3 to 5 x 10(4)-fold versus 5 x 10(3)-fold). Inhibition by antithrombin was only slightly affected for the factor IXa variant with the prothrombin loop sequence, whereas factor IXa variants containing the analogous residues of factor VII or factor X were virtually insensitive to antithrombin inhibition. In the presence of heparin, however, all chimeric factor IXa variants formed complexes with antithrombin. Thus the cofactors heparin and factor VIIIa have in common that they both alleviate the deleterious effects of mutations in the factor IX loop 199-204. Collectively, our data demonstrate that loop 199-204 plays an important role in the interaction of factor IXa with macromolecular substrates.
Kolkman
J A
JA
Department of Plasma Protein Technology, CLB, Amsterdam, The Netherlands.
Christophe
O D
OD
Lenting
P J
PJ
Mertens
K
K
D000991:Antithrombins / Q000494:pharmacology; D001483:Base Sequence; D001665:Binding Sites; D015949:Factor IXa / Q000737:chemistry* / Q000235:genetics; D005167:Factor VII / Q000235:genetics; D015944:Factor VIIIa / Q000378:metabolism; D005170:Factor X / Q000235:genetics; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D009154:Mutation; D009838:Oligodeoxyribonucleotides; D011485:Protein Binding; D011516:Prothrombin / Q000235:genetics; D011993:Recombinant Fusion Proteins; D016415:Sequence Alignment; D013379:Substrate Specificity
D000991:Antithrombins; D009838:Oligodeoxyribonucleotides; D011993:Recombinant Fusion Proteins; D015944:Factor VIIIa; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X; D006493:Heparin; D015949:Factor IXa